Tyra Biosciences/$TYRA
1D1W1MYTD1Y5YMAX
Capital at risk
About Tyra Biosciences
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
- Ticker
- $TYRA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 87
- Headquarters
- Carlsbad, United States
- Website
- tyra.bio
Tyra Biosciences Metrics
BasicAdvanced
$1.5B
-
-$2.40
0.77
-
Price and volume
Market cap
$1.5B
Beta
0.77
52-week high
$40.65
52-week low
$11.82
Average daily volume
948K
Financial strength
Current ratio
14.905
Quick ratio
14.478
Long term debt to equity
0.014
Total debt to equity
0.016
Profitability
EBITDA (TTM)
-159.922
Management effectiveness
Return on assets (TTM)
-28.46%
Return on equity (TTM)
-45.31%
Valuation
Price to book
4.23
Price to tangible book (TTM)
4.23
Price to free cash flow (TTM)
-14.102
Free cash flow yield (TTM)
-7.09%
Free cash flow per share (TTM)
-1.778
Growth
Earnings per share change (TTM)
34.46%
3-year earnings per share growth (CAGR)
26.21%
What the Analysts think about Tyra Biosciences
Analyst ratings (Buy, Hold, Sell) for Tyra Biosciences stock.
Analyst projections of the future price of Tyra Biosciences stock.
Bulls say / Bears say
SURF302 produced a potentially compelling early efficacy signal: at 60 mg once daily, overall response rate was 79% and best overall complete-response rate was 64% across single- and multiple-marker lesions; in the single-marker subgroup, those figures were 100% and 75%, respectively. (Tyra Biosciences)
Dabogratinib’s initial safety profile supports its potential for chronic oral dosing: no clinically significant hyperphosphatemia, nail toxicity, or ocular toxicity was observed, no Grade 4 or 5 treatment-emergent adverse events occurred, and there were no dose reductions or treatment-related discontinuations at 60 mg. (Tyra Biosciences)
TYRA’s $353.9 million of cash, cash equivalents, and marketable securities as of June 30, 2026, was projected to fund operations into the second half of 2028, giving the company time to advance multiple clinical programs and pursue potential registrational studies. (SEC)
SURF302’s efficacy signal is based on only 26 evaluable patients, including 14 at the lead 60 mg dose, and the company cautions that preliminary results may change with additional follow-up and enrollment. (Tyra Biosciences)
TYRA still faces substantial clinical and regulatory execution risk: SURF302 must support a registrational strategy, while the BEACH301 pediatric readout was pushed to the end of Q1 2027 and SURF303 results are not expected until 2027. (Tyra Biosciences)
Shareholder dilution remains a material risk: TYRA reported issuing 4.69 million shares for $147.9 million of net proceeds in Q1 and subsequently disclosed capacity to sell up to an additional $250 million through an ATM offering. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2026.
Tyra Biosciences Financial Performance
Revenues and expenses
Tyra Biosciences Earnings Performance
Company profitability
Upcoming events
No upcoming events
Tyra Biosciences News
AllArticlesVideos
Funds containing Tyra Biosciences
AllUSDGBPEUR
Fund name | Fund size | $TYRA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.13% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.13% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.